Actinogen Medical Ltd has released a press release.
ACW randomizes first US participant in Alzheimers trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Actinogen Medical Limited on 6ix
Story so far
Earlier from Actinogen Medical
- Actinogen receives $9.0 million R&D tax incentive rebate
- ACW September 2024 quarterly activity report & Appendix 4C
- $3.0 million share purchase plan closes 1.3x oversubscribed
- ACW $11.1m capital raising to accelerate Alzheimers trial
- Pause in Trading
Later from Actinogen Medical
- ACW December 2024 quarterly activity report & Appendix 4C
- Peer-reviewed clinpharm manuscript published
- ACW HY25 results Advancing to latestage clinical development
- ACW conducts Type C meeting with FDA regarding depression
- Actinogen March 2025 quarterly activity report & Appendix 4C
Follow Actinogen Medical into a list and get an email when it puts out news.
Follow Actinogen Medical